Inspire Pharmaceuticals has announced that the FDA has sent the company a second
letter outlining steps needed before the agency can approve its dry eye drug,
diquafosol tetrasodium. Diquafosol tetrasodium is a P2Y2 receptor agonist, targeted
to treat dry eye disease through rehydration of the ocular surface.
Dry eye is a hard-to-treat condition in which a person's eyes produce too few tears, or tears of too poor quality, to lubricate the eye and keep it comfortable.